1. Sun Q., Yang Z., Lin M., et al. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers. Biomaterials, 2021, 269, 120648. (IF: 15.304) 2. Sun Q., You Q., Pang X., et al. A photoresponsive and rod-shape nanocarrier: Single wavelength of light triggered photothermal and photodynamic therapy based on AuNRs-capped & Ce6-doped mesoporous silica nanorods. Biomaterials, 2017, 122: 188-200. (IF: 15.304) 3. Sun Q., You Q., Wang J., et al. Theranostic nanoplatform: Triple-modal imaging-guided synergistic cancer therapy based on liposome-conjugated mesoporous silica nanoparticles. ACS Appl. Mater. Interfaces, 2018, 10, 1963-1975. (IF: 10.383) 4. Yang Z., Du Y., Sun Q., et al. Albumin-based nanotheranostic probe with hypoxia alleviating potentiates synchronous multimodal imaging and phototherapy for glioma. ACS Nano, 2020, 14, 6191-6212. (IF= 18.027) 5. Du Y., Yang Z., Sun Q., et al. Engineered Microglia Potentiate the Action of Drugs against Glioma Through Extracellular Vesicles and Tunneling Nanotubes[J]. Advanced Healthcare Materials. (IF= 11.092) 6. You Q., Sun Q., Yu, M., et al. BSA−bioinspired gadolinium hybrid-functionalized hollow gold nanoshells for NIRF/PA/CT/MR quadmodal diagnostic imaging guided photothermal/photodynamic Cancer Therapy. ACS Appl. Mater. Interfaces, 2017, 9, 40017-40030. (IF: 10.383) 7. You Q., Sun Q., Wang J., et al. A single-light triggered and dual-imaging guided multifunctional platform for combined photothermal and photodynamic therapy based on TD-controlled and ICG-loaded CuS@mSiO2. Nanoscale, 2017, 9, 3784-3796. (IF: 8.307) 8. Lu Q., Sun Q., Li P., et al. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. J. Mater. Chem. B., 2019, 7, 2499-2511. (IF= 7.571) 9. Song Y., Wang J., Liu L., Sun Q., et al. One-pot synthesis of a bismuth selenide hexagon nanodish complex for multimodal imaging-guided combined antitumor phototherapy. Mol. Pharm. 2018, 15, 1941-1953. (IF= 5.364) 10. Lin M., Yang Z., Yang Y., Peng Y., Li J., Du Y., Sun Q., Gao D., et al. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today, 2022, 42:101359-. (IF= 18.962) |
